GSK, SK Bioscience to test COVID-19 vaccine against AstraZeneca shot (updated)

SK Bioscience Co

31/08/2021 07:24

(Adds details on trial, background)
    Aug 31 (Reuters) - Britain's GSK  GSK.L  and South Korea's
SK Bioscience  302440.KS  said on Tuesday the drugmakers have
begun a late-stage trial of their COVID-19 vaccine candidate to
assess immune response when compared with AstraZeneca's  AZN.L 
approved shot.
    The trial will enrol around 4,000 candidates globally and
test SK's COVID-19 vaccine candidate, GBP510, in combination
with GSK's vaccine booster following positive early-stage data https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=91&
 earlier this month.
    Results from the GSK-SK study are expected in the first half
next year, and the vaccine will be supplied worldwide through
the World Health Organization-led vaccine sharing programme
COVAX if approved, the companies said.  urn:newsml:reuters.com:*:nRSe1086Ka

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak
Dasgupta)
 ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793))